Related Experiment Videos
[Phase I clinical study of MX2 (KRN 8602)]
1Chiba Cancer Center Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 1, 1990
Summary
KRN 8602, a novel anthracycline analog, shows promise as an effective antineoplastic drug with reduced side effects. Early clinical trials indicate its potential against resistant tumors and a manageable toxicity profile, warranting further investigation.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Context:
- Current anthracyclines have limitations in efficacy and toxicity.
- Development of novel antineoplastic agents is crucial for improved cancer treatment.
- Adriamycin resistance poses a significant challenge in chemotherapy.
Purpose:
- To evaluate the safety and toxicity of KRN 8602 in a Phase I clinical study.
- To assess the preliminary efficacy of KRN 8602 in cancer patients.
- To compare KRN 8602's side effect profile with existing anthracyclines.
Summary:
- KRN 8602 (3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride) demonstrated dose-limiting myelosuppression (leukopenia, neutropenia) with a maximum tolerated dose (MTD) of 30 mg/m2.
- Common side effects included nausea and vomiting at doses >10 mg/m2; however, alopecia and cardiotoxicity were not observed.
- A notable case of regression in metastatic breast carcinoma was observed in a patient previously treated with adriamycin, suggesting efficacy against resistant tumors.
Impact:
- KRN 8602 exhibits a potentially improved safety profile compared to traditional anthracyclines.
- The drug shows promise in treating anthracycline-resistant cancers.
- Preliminary Phase I data strongly support further clinical investigation of KRN 8602.